The IPO market is playing the waiting game. IPO investors are anticipating Anthropic’s blockbuster filing – possibly by the end of the week. The IPO Calendar shows no large IPOs on tap for the week of Oct. 19, 2026. (This is the 39th anniversary of Black Monday.) Two small deals may get priced this week.
Meanwhile, AI-focused Nscale is getting pushback from IPO investors over its valuation, Bloomberg reported.
Biotech IPOs defied the market’s cautious mood last week, Both biotech deals on last week’s IPO Calendar booked decent gains.
Cancer biotech Iambic Therapeutics (IAM) settled at $23.81 on Friday, Oct. 16, 2026, up $4.90 for a gain of 25.91 percent for the day. At Friday’s close, Iambic’s stock finished the week up 48.81 percent from its $16.00 IPO price on Wednesday night, Oct. 14.
On Thursday, Oct. 15, Iambic’s stock edged higher in its first day of NASDAQ trading – – but it gained steam later in the day. At Thursday’s closing bell, Iambic’s stock was at $18.91 – up $2.91 for a gain of 18.19 percent from its $16.00 IPO price on Oct. 15, its first day of NASDAQ trading.
City Therapeutics (CTY) ended Friday’s session at $22.40, up $4.40 from its IPO price of $18.00, for a gain of 24.44 percent on its first day of NASDAQ trading. City’s IPO was priced on Thursday night, Oct. 15.
City Therapeutics has three leading drug candidates – one intended to prevent strokes as well as one focused on Stargardt disease, a rare inherited disease that can cause blindness in children and young adults, and another designed to treat chronic anemia.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.